摘要
目的探讨老年晚期非小细胞肺癌(NSCLC)患者行血管内介入治疗的临床疗效与安全性。资料与方法搜集2005年至2009年间在本院行介入治疗的老年晚期NSCLC患者资料共74例,分别采用支气管动脉灌注化疗50例,化疗栓塞治疗24例,每月一次,共行2～5次;每次治疗前后行血生化及心功能检查,至少治疗2次后复查CT、DSA,行疗效评估和生存期随访。结果治疗组中平均年龄75.27岁,平均治疗3.05次,全组有效率60.81%,临床受益率93.24%,中位生存期12.21个月。其中动脉灌注组的有效率与中位生存期分别为52.00%和12个月,而化疗栓塞组分别为79.17%和17个月,两组比较有显著性差别(P值分别为0.025和0.0016);主要毒副反应为Ⅰ～Ⅱ度骨髓抑制和消化道反应。结论血管内介入治疗老年晚期NSCLC的药物用量及临床操作较安全,临床疗效较为可靠。
Objective To evaluate the safety and clinical efficacy of interventional angiographic therapy for advanced non-small cell lung cancer（NSCLC） In old people.Materials and Methods Seventy-four old patients with advanced NSCLC were treated from 2004 to 2009.Fifty patients were treated with bronchial arterial infusion（BAI） and 24 patients were treated with bronchial arterial chemoembolization（BACE）.The treaments were repeated once a month.After two cycles of therapy,the clinical efficacy and safety were evaluated by means of blood biochemical results,,cardiac function examinations,CT and DSA images.Results The mean age of patients was 75.27 years and average therapy cycle was 3.05.The total response rate and the clinical benefit response（CBR） rate was 60.81% and 93.24%.The median survival time was 14 months.Among two groups,the total response rate and the median survival time were 52.00% and 12months in BAI group,76.67% and 17 months in BACE group.There was significance difference between two groups（P=0.05,0.0016）.The major side effects were gradeⅠ-Ⅱ bone marrow suppression and digestive response.Conclusion The interventional angiographic therapy was a safety and useful method in treatment the elder patients with advanced NSCLC.
出处
《临床放射学杂志》
CSCD
北大核心
2010年第9期1238-1240,共3页
Journal of Clinical Radiology
关键词
肺癌
非小细胞
介入治疗
血管内
Lung cancer Non-small cell Interventional therapy Angiograph
